Hikal Limited will transfer unclaimed final dividends for the financial year 2018-19 and the corresponding equity shares to the Investor Education and Protection Fund (IEPF) on September 5, 2026. This action follows the provisions of Section 124 of the Companies Act, 2013, and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016. The transfer applies to dividends that have remained unclaimed for seven or more consecutive years.

The company has sent individual communications to shareholders whose shares are liable for transfer and published reminder letters in newspapers including Business Standard and Mumbai Lakshadeep on May 30, 2026. Shareholders holding shares in physical form will have new share certificates issued to the IEPF, automatically cancelling the original certificates. For dematerialized shares, the company will instruct depositories to transfer the shares to the IEPF's demat account.

Shareholders must claim their unclaimed dividends by September 5, 2026, to prevent the transfer of their equity shares. Claims should be submitted to the company's Registrar and Transfer Agent, MUFG Intime India Private Limited, along with necessary documents such as the Investor Service Request Form and a cancelled cheque leaf. Any benefits accruing on the transferred shares will also be issued to the IEPF Authority.

Once the shares are transferred, shareholders can reclaim both the dividend and the shares from the IEPF Authority by following the procedure prescribed under the Rules, which involves filing web form IEPF 5. The company has made the complete details of affected shareholders, including folio numbers and Demat account details, available on its website.

Hikal Limited has rescheduled its earnings conference call to discuss its financial and operational performance for the quarter and fiscal year ended March 31, 2026. The meeting, originally set for 4:30 PM IST, will now be held on May 27, 2026, at 5:30 PM IST. This adjustment provides investors and analysts a revised opportunity to hear directly from the company's leadership regarding the results for Q4 and FY26.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation serves as a formal update to the earlier communication dated May 20, 2026, ensuring all stakeholders are aligned with the new timing.

Key members of the management team will lead the discussion. The participants include Mr. Sameer Hiremath, Vice Chairman and Managing Director; Mr. Kuldeep Jain, Chief Financial Officer; Mr. Anish Swadi, Senior President, Business Transformation and Animal Health; and Mr. Manoj Mehrotra, President, Pharmaceuticals Business.

The conference call offers universal access for domestic and international investors. Participants can join via specific dial-in numbers provided for various regions, including Hong Kong, Singapore, the UK, and the USA. Strategic Growth Advisors Pvt. Ltd. is handling the RSVP coordination for the event.